Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity

Justine Badée1, Nahong Qiu2, Abby C Collier3

  • 1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida at Lake Nona, Orlando, Florida, USA.

Insights

Understanding the postnatal development of hepatic UDP-glucuronosyltransferase (UGT) enzymes is crucial for pediatric drug dosing. This study characterized UGT isoform maturation, revealing significant age-dependent changes in glucuronidation activity essential for pharmacokinetic predictions.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Pediatrics

Background:

  • Accurate prediction of pediatric drug pharmacokinetics requires understanding hepatic UDP-glucuronosyltransferase (UGT) enzyme development.
  • The maturation rates of specific hepatic UGT isoforms represent a significant knowledge gap in pediatric drug metabolism.

Purpose of the Study:

  • To establish age-associated changes in the glucuronidation activity of 10 major human hepatic UGT isoforms.
  • To characterize the postnatal ontogeny profiles of these UGT enzymes for improved drug disposition prediction in children.

Main Methods:

  • Human liver microsomes from pediatric and adult donors were used.
  • Activity rates of 10 UGT isoforms were assessed using 19 in vitro UGT probe substrates and drugs.
  • Correlations in glucuronidation activities were analyzed to establish ontogeny.

Main Results:

  • Postnatal development of hepatic UGTs is isoform-dependent.
  • Maximal adult activity was reached at different ages, from within a month to adolescence.
  • Ontogeny was established for UGT1A1, UGT1A4, UGT2B7, UGT2B10, and UGT2B15.

Conclusions:

  • This study provides extensive characterization of hepatic UGT ontogeny profiles.
  • These findings are instrumental for predicting drug disposition using in vitro-in vivo extrapolation.
  • Results aid in verifying pharmacokinetic predictions in pediatric patients via physiologically based pharmacokinetic modeling.

Related Concept Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Here, we present a protocol for measurement of hepatic venous pressure gradient (HVPG),the gold standard to diagnose clinically significant portal hypertension. Moreover, we describe how to perform a transjugular liver biopsy within the same...
22.5K
Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells11:44

Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells

Here, we present a novel humanized mouse liver model generated in Alb-toxin receptor mediated cell knockout (TRECK)/SCID mice following the transplantation of immature and expandable human hepatic stem...
11.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Here, we present a protocol how to perform an isolated liver perfusion (IHP) with melphalan and we also discuss IHP as a treatment option for liver metastases of uveal...
13.9K
Functional Human Liver Preservation and Recovery by Means of Subnormothermic Machine Perfusion08:54

Functional Human Liver Preservation and Recovery by Means of Subnormothermic Machine Perfusion

We describe a method of ex vivo machine perfusion of human liver grafts at subnormothermic temperature (21...
17.4K
Isolation of Marginating Hepatic Leukocytes from a Mouse Liver03:42

Isolation of Marginating Hepatic Leukocytes from a Mouse Liver

In this video, we demonstrate the isolation of marginating hepatic leukocytes from mouse liver by forced...
633
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery04:46

Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery

The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor...
596